Transcript 0:00 The number one thing I would tell you in biotech is that there, uh, if you look at the statistics of the drugs that become blockbusters and when they had coverage, and when the coverage by these analysts said they would be successful, basically none of them. 0:16 They're... The, the fa- If you ever get behind a biotech and y- you say, "You know what? The analysts are not with me," that's a good thing, not a bad thing. 0:24 [upbeat music] On this episode of Early Bird, Joe Springer, host of Investors Club. 0:33 Joe joins the podcast today to talk about biotech stocks in 2023, including why this is the year to buy into the sector, and a look at Joe's top biotech stock picks. 0:46 If you're an investor looking to stay on top of the latest market trends, then you're listening to the right podcast. This is Early Bird, and I'm your host, Steven Lerner. 0:56 Before we get to today's discussion, let me tell you where you can save time and beat the market through Early Bird, a free daily email newsletter featuring commentary about the latest trends in stocks, cryptocurrency, and equity crowdfunding. 1:11 Early Bird is designed to help individual and non-professional investors stay on top of all the critical investing trends. The newsletter is 100% free and is sent to your email box each weekday morning. 1:24 Subscribe to Early Bird for free at www.earlybird.email. Once again, that's earlybird.email. And now, today's discussion. All right, Joe, welcome to the Early Bird Podcast. How are you doing? Hi, Steven. I'm doing great. 1:41 Thank you so much for having me here. I really appreciate, uh, r- really appreciate your invitation. And y- and I've... And to find out a little bit more about you is really nice. 1:48 You and I are sort of doing the same thing. [laughs] You sort of started a little financial media about a year and a half ago, so that's pretty good stuff. Good to meet you. Yeah, absolutely. 1:56 It's, it's, it's a great time for, to be doing this sort of thing, and interesting topic that you're gonna be talking about right now will be biotech stocks. 2:04 But before we do that, uh, Joe, um, in about 30 seconds or so, what, what should the audience know about you? 2:12 Uh, well, I was a s- I was a stock analyst in my previous life, became the number one ranked stock analyst in the world. Why don't I did some other stuff. 2:19 This is the, the fourth time I'm doing a show on the stock market, sort of like Mad Money. I'm, I lo- I love the idea of, of doing a show. Here's what I think about the stock market, really. 2:28 I, I can't get away from this. This is the fourth time. Investors Club is the fourth time I'm doing it, and I've been doing it for a year and a half now. Every day is the first time I have a real go at it. 2:35 So, uh, the, uh... We're doing the best research and analysis for the regular investors because the financial media is controlled by the institutions. So it's, it's up to you and me, Steven, to now... 2:44 People like us, that's the new media, is, is regular people, uh, saying, "Let's get together and make a little community and do the best research, uh, so that we can get to the real answers." 2:52 And so that's what we're doing with Investors Club. Yeah. I'm glad to hear it. I mean, that's... We're trying to, you know, make sure we spread awareness, give people information, help people out. 3:00 I think that's all very important. Um, biotech stocks. You know, um, of all the opportunities in the market, of all the sectors right now, why do you think this is a good time here in 2023 to go after biotech stocks? 3:16 Well, we know that it's been such a rough... You and I came in, Steven, and started our companies about a year and a half ago, right at the end of the bull market. 3:23 [laughs] So it's been rough for a year and a half for the growth in innovation stocks, and that is when you buy. You don't buy after things have been running for a year and a half. 3:33 You buy when they've been getting killed for a while. So this is, right now, we're all the way back to 2015 levels. We've lost eight years. 3:42 It's been an, a lost eight-year period, almost a lost decade in biotech, and we know the sectors rotate. There's different sectors go in and out of fashion. 3:50 Uh, if, if you were to rotate in and out of different stocks, a, a certain stock may go to zero, but the life sciences industry is not going to zero. 3:57 And it's been out of fashion for a long time, and it will have its day. And this is looking like a great time to rotate in. And to wit, we just had a takeout, uh, ex- this was, this was a couple weeks ago from the... 4:09 This is, this is the middle of March. Middle of March, there was a takeout with a- Mm.... 273% premium. Uh, and so that's sort of indicating the, the, the, the, the huge values that how depressed these levels are. 4:19 Artificially depressed, if you ask me. And then also, uh, our... 4:22 when g- getting, speaking of the artificial depression, we know from things like GameStop, AMC, these are the companies, these growth and innovation companies that don't have earnings, uh, to, to pay dividends and things. 4:32 They're the ones that get artificially shorted with phantom shares and things like that. 4:36 And for the first time in decades, these CEOs are fighting back with things like digital dividends, dual listings, defamation cases against the short and distorts. 4:48 And it's, uh, this is the first time ever, and we're seeing some real traction. So this is looking like quite a time to, uh, to get into the biotech sector. Yeah. I, I mean, you brought up a great point earlier. 4:58 The prices have dropped. Uh, y- I think you mentioned 2015 levels, um, especially with what we've seen the past few weeks. 5:05 Y- y- but even that, just the past year or two, it's, it's dropped tremendously in the biotech space. Do you think this is the bottom though, or could we keep dropping in the future? 5:16 It's a terrific question, and I think that I, I wouldn't try to, to bottom tick the market. It's just too difficult. I would buy when there's blood in the streets. To pick the very, very bottom is... 5:29 I d- I just think it's too difficult. And, and to... 5:31 For example, in, in, in, in the, the crash of 2000, 2001, the crash of 2007, 2008, 2009, uh, if you could go back in time without looking at a, without looking at, uh, uh, the, the charts again to pick the exact day, you'd probably... 5:46 You know, you'd get in, in the crash. You wouldn't know the exact day, and you'd wait a while and be really, do really, really well.So to, to pick the exact day, I, I don't know. 5:55 But I do think this is, this is real blood in the streets. We'll look back at lo- losing eight years and, uh, and we're, we're less than 50%. We've lost more than half from the peak a year, a year and a half ago. Mm. 6:06 Uh, so it, it looks, it looks to me like these are sufficiently depressed levels. But it's a great question. Is this the very bottom? I, I don't know. I'm not trying to pick the very bottom. It's a terrific question. 6:16 Yeah. So I mean, I always tell listeners, uh, speak to a financial advisor when you're making these stock decisions. And you brought up so many great points, Joe. 6:23 I mean, we know the biotech space is a great pla- could be a great place to be depending on what an investor's looking for. There's a lot going on in the space. Um, you came prepared. 6:31 You have a list of stocks in biotech that you think maybe- I do... this might be a good opportunity to take a look at. Um, what, what's the top stock that you have on your list in biotech? 6:42 Well, the, the one I've been writing about, uh, the one I've been talking about the most, and there's the most excitement about, of all the stocks I talk about, is Cassava Sciences, and that's because Alzheimer's disease is the biggest unmet medical need in the world. 6:55 The march of technology, science and technology the last few decades has worked in cancer, heart disease, many rare diseases. 7:04 Uh, if you have those, those, those a- awful diseases, your, uh, outcomes have gotten better over time. And then the, the, the, the, the... Uh, and by all the measures. 7:13 Really everything has gotten a little bit better and a little bit better and gradually better and better, except Alzheimer's disease. It's the sad outlier. Mm. 7:20 And with, we know that, uh, age is the number one risk factor, and the baby boom generation is all moving in across the world into the Alzheimer's age, and it's an enormous, enormous problem now, uh, costing around half a trillion dollars in both direct, combined, combining direct spend and indirect spend because it's a disease of caretakers. 7:40 And, uh, this is only gonna, uh, go much, much higher, about triple, maybe even triple. Uh, so anyway, that has been, there's been more than 100 failed drugs in, in Alzheimer's. 7:51 There's still, even with Leqembi's approval, it does not look like a good therapy at all. Uh, and so Cassava Sciences has sunifiram. 7:57 It looks like we know that, uh, Alzheimer's disease has a misfolding protein c- uh, component. 8:02 This is targeting the misfolded protein filament, which looks like it's at the one of, either the root cause or one of the root causes of Alzheimer's disease. 8:10 And it looks like it is, in fact, uh, interfering with the gradual downward trajectory of Alzheimer's that leads to death, and people are doing very well in these trials. 8:19 And, uh, we've interviewed four people with family members in the trials, and they're doing very well. Mm. And they just, yeah, they just had a trial of 216 people in a single arm study. 8:30 Two hun- uh, 125 of those were considered by their doctors to be responders, that was a year long, and sent into the second leg of the study, which is placebo controlled. 8:38 So that was most people were considered to respond. And, uh, so, so it's just looking really promising. 8:44 They're almost, uh, they should, uh, fully enroll their phase threes by the end of the year, if not a little bit sooner. 8:50 And so that one, they're, they're a billion dollar about market cap right now, but that opportunity is at least 100 billion. Yeah. Wow. 8:57 I mean, it's certainly an, an important space to be, to be able to provide, um, pharmaceuticals for, for those types of patients. It, it, it's such a horrible disease. 9:07 And so Cassava Sciences, I, I see that's the top of your list. Uh, real quick, what, what other, um, what other biotech stocks do you see as good plays in 2023? 9:17 Well, I'll bring up one that's doing very well already, but it's just had a great event, and, and I love this company, and this is Fusion Pharmaceuticals. I recommended this one at $2 a few months ago. 9:27 It's already got up to five. Uh, but it is a... We, we know this is for oncology. We know radiation, people blast... Not people. 9:35 The- there's, with radiation is beamed from the outside to tumors to, uh, and it's effective, but it's also a scattershot approach. 9:42 So what Fusion is doing is they're taking radiation particles and delivering them internally using monoclonal antibodies or small molecules or peptides to deliver these, uh, radiated, radiated particles, alpha particles, to the tumor, uh, and to, to, to do the job the radiation does in a specific approach. 10:02 And they have an entire platform of this. 10:04 They have probably the very, very best experts in the world as the executive team, including a founding CEO, and they just raised money above where they were trading that day, which in this market, which is unheard of in the first place- Mm-hmm... 10:19 but in this market, it's very, it's really unheard of. And they did that. They were able to raise money to make an acquisition. 10:24 They're a s- very small early stage company, and they were able to raise money to acquire another company. 10:30 And so they're, they're looking, they're, they're a platform in oncology that looks very exciting with a terrific management team, and the market is, uh, is sending very encouraging signals on that one. 10:40 [upbeat music] Good to know. When we return, we'll hear from Joe about the pitfalls of biotech stocks and his advice for getting started with investing in biotech companies. 10:58 But first, let me tell you how you can become a more informed investor through Early Bird, a free daily email newsletter. 11:06 Early Bird has commentary on the latest events and trends in stocks, cryptocurrency, and crowdfunding. With Early Bird's daily week day email, investors can quickly stay on top of the trends and beat the market. 11:19 Subscribe to Early Bird for free at www.earlybird.email. Once again, that's earlybird.email. And now, back to today's discussion. 11:31 Uh, so Joe, today we're talking about biotech stocks, and you're listing some of your top plays for 2023, and we'll get back to that in just a second. But I just wanted to play devil's advocate real quick. Sure. 11:42 Uh, we talked about the benefits of this industry and why investors should get in. Um, there are a ton of risks, though, with biotech stocks. Many of them go belly up. Um, s- there, there's a lot of, uh, volatility. 11:53 Um, these stocks, some of them could be conceived as penny stocks. They may, they may not go anywhere. You might lose all your money. 11:59 Um, what do you say about the risks involved with biotech stocks?Well, in investing in general, the main trade-off is the more risk you take, uh, the more return you might get. 12:11 So in things like the risk-free rate, treasuries and things like that are traditionally very low because there's no risk. 12:17 And so in order to get a return, we're talking about like with Cassava, 100x or something like that. Mm-hmm. 12:21 In order to get a return, you're simply not gonna get, uh, the ability to get returns like that without taking big risks. So it's very true. This is growth and innovation. 12:30 Biotech specifically is a very risky area, and most companies will fail. Most investments in a single company will lose money. This is very similar to venture capital, where your winners must make up for your losers. 12:44 You may only have, uh, m- m- you may expect to have most of these be losers, but we just saw with Fusion, for example, it just got behind, uh, it just went to five. Who knows where it could go? Mm-hmm. 12:55 That one could be a big winner. The next Gileads, Regenerons, Amazons, these companies are out there. 13:00 And so this is the venture capital model where you are looking for 100xs or 10xs or 100xs anyway, uh, something like that, and you are not expecting everything. 13:09 If you want everything, most things to work out, you wanna diversify into dividend stocks. You're not gonna get doubles overnight, but you're not gonna lose your money overnight either. So there's... It's a great point. 13:18 There's a very high risk only for the very high risk tolerance. Mm-hmm. A great point you bring up there. High risk, high reward, take big swings. 13:27 Um, but why not just, you know, pick an ETF or a mutual fund that tracks biotech instead of picking individual stocks in the space? Well, in that case, let me introduce you to the stock of Zoma that I just recommended. 13:40 This is the kind of thing you're talking about. They... This is sort of the, uh... They... 13:45 What they do is they do royalties and milestones, so they have more than seventy drugs that they own a little portion of, and so they're divers- diversified. However, what they do differently is they invest early. 13:56 So phase two is, is really when things sink or swim because it's usually the first time when drugs are tested for efficacy in people. 14:04 So this is the first time when, when you see does it work or not, and most of them don't work. Uh, so something like one-third of them will, will be, will be positive enough in phase two to go on. 14:14 Something, something like a third or so. Mm-hmm. Uh, so anyway, so that's when they sink or swim. So that's when you get the, the big move, moves up or moves down a lot of times. And so that's when they're funding. 14:24 They're funding companies early and getting milestones and royalties. 14:29 So when a biotech, uh, makes a deal with Merck and gets to, to license their drug that the biotech developed and now Merck's l- selling it, and this biotech has-- gets the, the, the royalties. 14:40 The Zoma, this company Zoma, gets a portion of those royalties, and it has that deal with, I think, seventy-six drugs. So it's an interesting company, like, and they have a, a s- expertise in monoclonal antibodies. 14:51 That's th- their history. So then they switched about five years ago to this new model. So it's an interesting... 14:56 You get to have, to play these small biotechs and the most, uh, explosive part of the small biotechs while being diversified. So that's an interesting one. And that one also, if you wanna... 15:09 If you want income, that one also, Zoma A or Zoma O, it also has preferreds for income. Nice. That's a good mix right there. Yeah. Definitely interesting under the radar type of play in biotech. 15:21 Um, Joe, what, what other stocks do you have on your list as, as potential biotech opportunities in twenty twenty-three? Uh, well, SC Pharmaceuticals is one I recommended. They're very interesting. 15:32 SC Subcutaneous Pharmaceuticals. They... You get... When people have, uh, hypertension from retaining fluids from, uh, cardiovascular problems, uh, they... 15:42 From heart failure, they, uh, they have to go into the hospital and stay for days to get, uh, intravenous, uh, diuretics. This is a... This company has a... I got behind it before it was approved, and they got approved. 15:55 They got a device, you take it home, and it gives you subcutaneous diuretic at home. People's outcomes are better at home. It's much cheaper at home, and everybody prefers to be at home instead of the hospital. 16:04 Doctors wanna... A- a- all of the, uh, people wanted. The doctors that, uh, admit these patients into the hospital are dinged. 16:12 Hospitals know this is a big problem, so, uh, Medicare and Medicaid ding them up to three percent of their reimbursements if they allow these patients to be readmitted, and it's the doctors that are the fall guys for that, uh, the fall people for that. 16:23 So anyway, so all of the, uh, all of the stakeholders want this. It's, it's, uh, it's showing up in all the formularies, and that, that's one that's already approved. 16:31 And so that one looks like it's a now a sales story if the market wants it or not, and I think it does. So that one looks interesting. 16:38 And if you want one that's sort of like that, that is up for approval, coming up for approval, that is Milestone, which is MYST. 16:45 They have a device that you in-inhale up your nose to fix your, uh, tachycardia, which is a three times heart rate problem that some people go to the emergency room for. So th- those are... 16:55 There's two, there's two more there. They're sort of in the similar, similar veins, similar types of companies. Yeah. 17:02 I, I mean, these s- similar to the ones you mentioned before, they, they're certainly needed, uh, for patients, but they also have a good, interesting opportunity in front of them. 17:11 Um, you mentioned some really good biotech stocks. Um, real quick, what are, what, what are some other ones on your list? Yep. 17:18 So there's also, if you want another 100x, there's a company, Atire, with its, uh, ticker is LIFE. That one has... It still has two years in trials. But if, if you're looking for another one like Cassava, if I'm... 17:30 If you're looking for a real high upside- Mm-hmm... check out what you think that one could do in sales. 17:34 It looks like they might be able to do, uh, two billion dollars to three billion dollars in peak sales, and their market cap's only sixty million, so they'll probably have to raise money along the way. 17:44 But they've got a founding CEO. That, that's something we talk about all the time. Founding CEOs tend to outperform, especially in tough times like now. Uh, so that, that's one that is, is... 17:54 We talk about the, the venture capital aspect, the 100x. That's one that's a possibility. Mm-hmm. 17:58 The, the founder, um, thing you mentioned, that's interesting because, you know, it's almost like, as you mentioned before, being a V- VC, picking those types of stocks, stocks that are, have startups in nature but can grow into something more. 18:11 Um, Joe, I was wondering, what advice would you recommend to our listeners, retail investors out there, who are new to the biotech space, and they wanna get started in, in investing and doing research? 18:23 What would you recommend to them?Well, I just created a biotech boot camp, a two-day biotech boot camp that it's, it's a two-day video. 18:31 But by the time this comes out, we'll have already done it on, uh, March 25th and 26th. But you can take that class, and there's a book that goes with it. So there's a lot to know in biotech. 18:39 But the number one thing I would tell you in biotech is that there, uh, if you look at the statistics of the drugs that become blockbusters and when they had coverage and when the coverage by these analysts said they would be successful, basically none of them. 18:56 They're-- the, the fa- If you ever get behind a biotech and it, you say, "You know what? The analysts are not with me," that's a good thing, not a bad thing. 19:03 The-- Nobody, nobody knows what they're doing in the biotech space, and that's not my opinion. They're-- That's like empirical, like there's studies on it. Uh, and so the... And then the... 19:15 So along with that, as we know, uh, the financial media is controlled by the institutions. The institutions are not trying to help retail investors. They're trying to steal from them. 19:24 If a, if a stock is good, they want-- they say, "Sell it to us," not, "You should buy it." They tell you the opposite. 19:30 So you should do your own work knowing that those opportunities are out there, and the real experts are wrong. Empirically, they're wrong, and these opportunities are out there. 19:38 And the, the, the, the financial media is going to lie to you. So if you do your own work, the opportunities are there, and it's really a one-of-a-kind sector as far as these moves are out there. 19:50 The-- Every day you look at the biggest moves in the market, look in the pre-market or whatever, which, which stocks are up 100%. It, it's almost always small biotechs. Yeah. 19:58 It seems like whenever there, there's a biotech in the news, the, the reaction is, "Oh, why didn't I get on that earlier?" Yeah. Or it's the opposite. It's like, "Oh, boy, good thing I didn't get on board. 20:07 That- That's right. [laughs]... looks pretty bad." Uh, Joe, thank you so much for coming on the Early Bird Podcast, sharing your insights on biotech stocks, some of the best plays for 2023, the pros and the cons. 20:18 We really appreciate it. Thanks again. Uh, b-before we wrap up the, the podcast, I just have one final question for you, Joe, and it's the most important question for today's discussion. Uh- Right... 20:29 that question for you, Joe, is what fictional world or place would you like to visit? The 1990s. [laughs] Well, that wa- That's not a fictional world. [laughs] That's not a fictional place. [laughs] Uh, 20:47 let's see. It's the, it's some, some sort of, some, some form of the '90s- Mm-hmm... where we can all be friendly to each other again. Well, that sounds fictional enough. Okay. [laughs] Yeah, yeah, yeah. 20:58 [laughs] [outro music] Thank you again to Joe Springer for sharing your insights on biotech stocks, and thank you to everyone for listening to today's discussion. 21:13 We'll be back next week for another episode of Early Bird. Have a great day. [outro music]